A CRISPR Startup Bets on an “Umbrella” to Fix Broken Regulations
A new CRISPR startup, Aurora Therapeutics, is betting that regulators will create a new pathway for personalized gene-editing drugs. Their plan is to get a single treatment approved that can be tweaked for different mutations without new trials.